A Different Look at Premarital Hemoglobinopathy Screening in Primary Care

Mekik, Haluk; Çelik Güzel, Eda; ÇELIKKOL, ALIYE

doi:10.18521/ktd.983680

A Different Look at Premarital Hemoglobinopathy Screening in Primary Care

Eda ÇELİK GÜZEL, (Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi, Aile Hekimliği Anabilim Dalı, Tekirdağ, Türkiye)

Aliye ÇELİKKOL, (Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Tekirdağ, Türkiye)

Haluk MEKİK (Tekirdağ İl Halk Sağlığı Tıbbi Biyokimya Laboratuvarı, Tekirdağ, Türkiye)

KONURALP TIP DERGİSİ

4 1

Yıl: 2021 Cilt: 13 Sayı: 3 Sayfa Aralığı: 621 - 627 Metin Dili: İngilizce DOI: 10.18521/ktd.983680 İndeks Tarihi: 09-01-2022

A Different Look at Premarital Hemoglobinopathy Screening in Primary Care

Öz:

Objective: Despite the high prevalence of hemoglobinopathies (HBP), the most common single-gene disorders in Turkey, data in some regions are lacking. We aimed to evaluate the effectiveness of the hemoglobinopathy premarital screening program (PMS) and to investigate the contribution of efficient use of complete blood count (CBC) parameters on cost-effectivity. Methods: HMP diagnosed 49171 subjects in 4 years and CBC of subjects with HMP in a year were evaluated retrospectively. Results: The total incidence rate of HBP was 3.41%, β-thalassemia trait (β-TT) was 1.98%, HMP incidence in the PMS group was 2.43%, β-TT was 1.08%. Moreover, HbF, HbD, HbC, HbS, HbE and HbJ were detected with the incidences of 0.49%, 0.14%, 0.05%, 0.04%, 0.007% and 0.009%, respectively. RDW/MCH ratio compared to other indices was the most successful for both sexes in diagnostic efficiency of HBP (AUC: male:0.922 - female:0.961) and β-TT (AUC: male;0.928 - female:0.961). Conclusions: PMS was found to be an effective application program in HMP screening. RDW/MCH ratio was the most useful and easy parameter in detecting HBP and β-TT in PMS and in terms of reducing unnecessary test requests and cost-effectiveness in public health screenings.

Anahtar Kelime:

Birinci Basamakta Evlilik Öncesi Hemoglobinopati Taramasına Farklı Bir Bakış

Öz:

Amaç: Türkiye'de en sık görülen tek gen hastalıkları olan hemoglobinopatilerin (HBP) yüksek prevalansına rağmen, bazı bölgelerde veri bulunmamaktadır. Hemoglobinopati evlilik öncesi tarama programının (PMS) etkinliğini değerlendirmeyi ve tam kan sayımı (CBC) parametrelerinin etkin kullanımının maliyet-etkililiğe katkısını araştırmayı amaçladık. Gereç ve Yöntem: 4 yılda 49,171 HMP tanısı konan olgu ve bir yılda HMP’si olan olguların tam kan sayımları geriye dönük olarak değerlendirildi. Bulgular: HBP'nin toplam insidans oranı %3.41, β-talasemi taşıyıcılığı (β-TT) %1.98 bulundu. PMS grubunda HMP insidansı %2.43, β-TT %1.08 idi. Ayrıca HbF, HbD, HbC, HbS, HbE ve HbJ sırasıyla %0.49, %0.14, %0.05, %0.04, %0.007 ve %0.009 oranında tespit edildi. ROC analizinde diğer indekslere kıyasla RDW/MCH oranı, HBP (erkek:0.922- kadın:0.961) ve β-TT (erkek;0.928- kadın:0.961) tanısal etkinliğinde her iki cinsiyet için de en başarılıydı. Sonuç: PMS, HBP taramasında etkili bir uygulama programı olarak bulundu. RDW/MCH oranı; HBP ve β-TT'nin saptanmasında ve halk sağlığı taramalarında gereksiz test isteklerinin azaltılması ve maliyet etkinliği açısından en kullanışlı parametreydi.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Smiers FJ, Krishnamurti L, Lucarelli G. Hematopoietic Stem Cell Transplantation for Hemoglobinopathies: Current Practice and Emerging Trends. Pediatr Clin North Am. 2010;57(1):181–205.
2. Karimzaei T, Masoudi Q, Shahrakipour M, Navidiyan A, Jamalzae AA l. Q, Zoraqi Bamri A. Knowledge, Attitude and Practice of Carrier Thalassemia Marriage Volunteer in Prevention of Major Thalassemia. Glob J Health Sci. 2015;7(5):364–70.
3. Sağlık TC, Açsap B, Müdürlüğü G. Hemoglobinopati Kontrol Programı. [Internet] [cited 2021 Feb 25] Available from: https://hsgm.saglik.gov.tr/tr/cocukergen-tp-liste/hemoglobinopati-kontrol-program%C4%B1.htm
4. Cao A, Kan YW. The prevention of thalassemia. Cold Spring Harb Perspect Med. 2013;3(2).
5. Balci YI, Ergin A, Polat A, Atilgan T, Uzun U, Koyuncu H. Thalassemia premarital screening program: Public view, what has been done, what needs to be done? UHOD - Uluslararasi Hematol Derg. 2014;24(4):247–52.
6. Zlotogora J. Population programs for the detection of couples at risk for severe monogenic genetic diseases. Hum Genet; 2009; 126, p. 247–53.
7. Canatan D. Thalassemias and hemoglobinopathies in Turkey, Hemoglobin. Informa Healthcare; 2014;38 p. 305–7.
8. England JM, Fraser PM. Dıfferentıatıon Of Iron Defıcıency From Thalassæmıa Traıt By Routıne Blood-Count. Lancet. 1973;301(7801):449–52.
9. Mentzer WC. Dıfferentıatıon Of Iron Defıcıency From Thalassæmıa Traıt. Lancet. 1973;301. p. 882.
10. Shine I, Lal S. A Strategy To Detect Β-Thalassæmıa Mınor. Lancet. 1977;309(8013):692–4.
11. Urrechaga E, Hoffmann JJML. Critical appraisal of discriminant formulas for distinguishing thalassemia from iron deficiency in patients with microcytic anemia. Clin Chem Lab Med. 2017;55(10):1582–91.
12. Ricerca BM, Storti S, D’Onofrio G, Mancini S, Vittori M, Campisi S, et al. Differentiation of iron deficiency from thalassaemia trait: a new approach. Haematologica. 1987;72(5):409–13.
13. Uludaǧ A, Uysal A, Uludaǧ A, Ertekin YH, Tekin M, Kütük B, et al. Prevalence and mutations of β-thalassemia trait and abnormal hemoglobins in premarital screening in Çanakkale province, Turkey. Balk J Med Genet. 2016;19(1):29–34.
14. Sarper N, Şenkal V, Güray F, Şahin Ö, Bayram J. Premarital hemoglobinopathy screening in Kocaeli, Turkey: A crowded industrial center on the north coast of Marmara sea. Turkish J Hematol. 2009;26(2):62–6.
15. Canatan D, Kose MR, Ustundag M, Haznedaroglu D, Ozbas S. Hemoglobinopathy control program in Turkey. Community Genet. 2006 Apr;9(2):124–6.
16. Hashemizadeh H, Noori R. Premarital Screening of Beta Thalassemia Minor in north-east of Iran. Iran J Pediatr Hematol Oncol. 2013;3(1):210–5.
17. Ulutaş KT, Şahpaz F, Sarıcı İŞ, Uluganyan M, Akçimen B, Çelik M, et al. Evlilik öncesi hemoglobinopati taraması: Kadirli, Türkiye beta-talasemi açısından riskli bir bölge mi? Türk Biyokim Derg. 2014 ;39(3):357–61.
18. Belhoul KM, Abdulrahman M, Alraei RF. Hemoglobinopathy carrier prevalence in the United Arab Emirates: First analysis of the dubai health authority premarital screening program results. Hemoglobin. 2013;37(4):359–68.
19. Schoorl M, Schoorl M, Van Pelt J, Bartels PCM. Application of innovative hemocytometric parameters and algorithms for improvement of microcytic anemia discrimination. Hematol Rep. 2015;7(2):52–5.
20. Rahim F. Microcytic hypochromic anemia patients with thalassemia : GGGGenotyping approach. Indian J Med Sci. 2009;63(3):101–8.
21. Bhattacharyya KK, Chatterjee T, Mondal UB. A comprehensive screening program for β-thalassemia and other hemoglobinopathies in the Hooghly District of West Bengal, India, dealing with 21 137 cases. Hemoglobin. 2016;40(6):396–9.
22. Velasco-Rodríguez D, Blas C, Alonso-Domínguez JM, Vega G, Soto C, García-Raso A, et al. Cut-off values of hematologic parameters to predict the number of alpha genes deleted in subjects with deletional alpha thalassemia. Int J Mol Sci. 2017;18(12).
23. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
24. Xie YP, Cao YP, Zhu XJ, Liu HJ, Liu J, Zhou WJ, et al. Values of Hematological Indicators in the Screening of α-Thalassemia in Fujian Area of China. Zhongguo shi yan xue ye xue za zhi. 2019;27(1):165–9.
25. Sudmann ÅA, Piehler A, Urdal P. Reticulocyte hemoglobin equivalent to detect thalassemia and thalassemic hemoglobin variants. Int J Lab Hematol. 2012;34(6):605–13.
26. Winichagoon P, Kumbunlue R, Sirankapracha P, Boonmongkol P, Fucharoen S. Discrimination of various thalassemia syndromes and iron deficiency and utilization of reticulocyte measurements in monitoring response to iron therapy. Blood Cells, Mol Dis. 2015;54(4):336–41.
27. Srisupundit K, Piyamongkol W, Tongsong T. Comparison of red blood cell hematology among normal, α-thalassemia-1 trait, and hemoglobin Bart’s fetuses at mid-pregnancy. Am J Hematol. 2008;83(12):908–10.
28. Bhattacharyya R, Iyer P, Phua GC, Lee JH. The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review. Pulm Ther. 2020;6(2):215–31.
29. Chatterjee T, Chakravarty A, Chakravarty S. Population screening and prevention strategies for thalassemias and other hemoglobinopathies of Eastern India: Experience of 18,166 cases. Hemoglobin. 2015;39(6):384–8.
30. Charoenkwan P, Taweephol R, Sirichotiyakul S, Tantiprabha W, Sae-Tung R, Suanta S, et al. Cord blood screening for Α-thalassemia and hemoglobin variants by isoelectric focusing in northern Thai neonates: Correlation with genotypes and hematologic parameters. Blood Cells, Mol Dis. 2010;45(1):53–7.

APA	Çelik Güzel E, ÇELIKKOL A, Mekik H (2021). A Different Look at Premarital Hemoglobinopathy Screening in Primary Care. , 621 - 627. 10.18521/ktd.983680
Chicago	Çelik Güzel Eda,ÇELIKKOL ALIYE,Mekik Haluk A Different Look at Premarital Hemoglobinopathy Screening in Primary Care. (2021): 621 - 627. 10.18521/ktd.983680
MLA	Çelik Güzel Eda,ÇELIKKOL ALIYE,Mekik Haluk A Different Look at Premarital Hemoglobinopathy Screening in Primary Care. , 2021, ss.621 - 627. 10.18521/ktd.983680
AMA	Çelik Güzel E,ÇELIKKOL A,Mekik H A Different Look at Premarital Hemoglobinopathy Screening in Primary Care. . 2021; 621 - 627. 10.18521/ktd.983680
Vancouver	Çelik Güzel E,ÇELIKKOL A,Mekik H A Different Look at Premarital Hemoglobinopathy Screening in Primary Care. . 2021; 621 - 627. 10.18521/ktd.983680
IEEE	Çelik Güzel E,ÇELIKKOL A,Mekik H "A Different Look at Premarital Hemoglobinopathy Screening in Primary Care." , ss.621 - 627, 2021. 10.18521/ktd.983680
ISNAD	Çelik Güzel, Eda vd. "A Different Look at Premarital Hemoglobinopathy Screening in Primary Care". (2021), 621-627. https://doi.org/10.18521/ktd.983680

APA	Çelik Güzel E, ÇELIKKOL A, Mekik H (2021). A Different Look at Premarital Hemoglobinopathy Screening in Primary Care. KONURALP TIP DERGİSİ, 13(3), 621 - 627. 10.18521/ktd.983680
Chicago	Çelik Güzel Eda,ÇELIKKOL ALIYE,Mekik Haluk A Different Look at Premarital Hemoglobinopathy Screening in Primary Care. KONURALP TIP DERGİSİ 13, no.3 (2021): 621 - 627. 10.18521/ktd.983680
MLA	Çelik Güzel Eda,ÇELIKKOL ALIYE,Mekik Haluk A Different Look at Premarital Hemoglobinopathy Screening in Primary Care. KONURALP TIP DERGİSİ, vol.13, no.3, 2021, ss.621 - 627. 10.18521/ktd.983680
AMA	Çelik Güzel E,ÇELIKKOL A,Mekik H A Different Look at Premarital Hemoglobinopathy Screening in Primary Care. KONURALP TIP DERGİSİ. 2021; 13(3): 621 - 627. 10.18521/ktd.983680
Vancouver	Çelik Güzel E,ÇELIKKOL A,Mekik H A Different Look at Premarital Hemoglobinopathy Screening in Primary Care. KONURALP TIP DERGİSİ. 2021; 13(3): 621 - 627. 10.18521/ktd.983680
IEEE	Çelik Güzel E,ÇELIKKOL A,Mekik H "A Different Look at Premarital Hemoglobinopathy Screening in Primary Care." KONURALP TIP DERGİSİ, 13, ss.621 - 627, 2021. 10.18521/ktd.983680
ISNAD	Çelik Güzel, Eda vd. "A Different Look at Premarital Hemoglobinopathy Screening in Primary Care". KONURALP TIP DERGİSİ 13/3 (2021), 621-627. https://doi.org/10.18521/ktd.983680